Skip to main content
Top
Published in: Supportive Care in Cancer 5/2009

01-05-2009 | Original Article

Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting

Authors: Suzanna M. Zick, Mack T. Ruffin, Julia Lee, Daniel P. Normolle, Rivka Siden, Sara Alrawi, Dean E. Brenner

Published in: Supportive Care in Cancer | Issue 5/2009

Login to get access

Abstract

Goals of work

Ginger has been used to treat numerous types of nausea and vomiting. Ginger has also been studied for its efficacy for acute chemotherapy-induced nausea and vomiting (CINV). However, its efficacy for delayed CINV in a diverse oncology population is unknown.

Materials and methods

We performed a randomized, double-blind, placebo-controlled trial in 162 patients with cancer who were receiving chemotherapy and had experienced CINV during at least one previous round of chemotherapy. All participants were receiving a 5-HT3 receptor antagonists and/or aprepitant. Participants were randomized to receive either 1.0 g ginger, 2.0 g ginger daily, or matching placebo for 3 days. The primary outcome was change in the prevalence of delayed CINV. Secondary outcomes included acute prevalence of CINV, acute and delayed severity of CINV, and assessment of blinding.

Main results

There were no differences between groups in the prevalence of delayed nausea or vomiting, prevalence of acute CINV, or severity of delayed vomiting or acute nausea and vomiting. Participants who took both ginger and aprepitant had more severe acute nausea than participants who took only aprepitant. Participants were able to accurately guess which treatment they had received. Ginger appeared well tolerated, with no difference in all adverse events (AEs) and significantly less fatigue and miscellaneous AEs in the ginger group.

Conclusions

Ginger provides no additional benefit for reduction of the prevalence or severity of acute or delayed CINV when given with 5-HT3 receptor antagonists and/or aprepitant.
Literature
3.
go back to reference Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472–4478 doi:10.1200/JCO.2006.05.6382 PubMedCrossRef Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472–4478 doi:10.​1200/​JCO.​2006.​05.​6382 PubMedCrossRef
6.
go back to reference Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497–503 doi:10.1007/s00520-006-0173-z PubMedCrossRef Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497–503 doi:10.​1007/​s00520-006-0173-z PubMedCrossRef
10.
go back to reference de Wit R, Herrstedt J, Rapoport B et al (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21(22):4105–4111 doi:10.1200/JCO.2003.10.128 PubMedCrossRef de Wit R, Herrstedt J, Rapoport B et al (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21(22):4105–4111 doi:10.​1200/​JCO.​2003.​10.​128 PubMedCrossRef
11.
go back to reference Fergusson D, Glass K, Waring D, Shapiro S (2004) Turning a blind eye: the success of blinding reported in a random sample of randomized, placebo controlled trials. BMJ 328:7437 Fergusson D, Glass K, Waring D, Shapiro S (2004) Turning a blind eye: the success of blinding reported in a random sample of randomized, placebo controlled trials. BMJ 328:7437
12.
go back to reference Feyer P, Kleeberg UR, Steingraber M, Gunther W, Behrens M (2008) Frequency of side effects in outpatient cancer care and their influence on patient satisfaction—a prospective survey using the PASQOC(R) questionnaire. Support Care Cancer 16:567–575 doi:10.1007/s00520-008-0422-4 PubMedCrossRef Feyer P, Kleeberg UR, Steingraber M, Gunther W, Behrens M (2008) Frequency of side effects in outpatient cancer care and their influence on patient satisfaction—a prospective survey using the PASQOC(R) questionnaire. Support Care Cancer 16:567–575 doi:10.​1007/​s00520-008-0422-4 PubMedCrossRef
16.
go back to reference Henry DH, Viswanathan HN, Elkin EP, Traina S, Wade S, Cella D (2008) Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer 16:791–801 doi:10.1007/s00520-007-0380-2 PubMedCrossRef Henry DH, Viswanathan HN, Elkin EP, Traina S, Wade S, Cella D (2008) Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer 16:791–801 doi:10.​1007/​s00520-007-0380-2 PubMedCrossRef
17.
go back to reference Hoffman D (1983) The new holistic herbal. Element Books Limited, Shaftesbury, Dorset Hoffman D (1983) The new holistic herbal. Element Books Limited, Shaftesbury, Dorset
18.
go back to reference Huang QR, Iwamoto M, Aoki S, Tanaka N, Tajima K, Yamahara J, Takaishi Y, Yoshida M, Tomimatsu T, Tamai Y (1991) Anti-5-hydroxytryptamine3 effect of galanolactone, diterpenoid isolated from ginger. Chem Pharm Bull (Tokyo) 39(2):397–399 Huang QR, Iwamoto M, Aoki S, Tanaka N, Tajima K, Yamahara J, Takaishi Y, Yoshida M, Tomimatsu T, Tamai Y (1991) Anti-5-hydroxytryptamine3 effect of galanolactone, diterpenoid isolated from ginger. Chem Pharm Bull (Tokyo) 39(2):397–399
21.
go back to reference Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932–2947PubMedCrossRef Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932–2947PubMedCrossRef
22.
go back to reference Krishnakantha TP, Lokesh BR (1993) Scavenging of superoxide anions by spice principles. Indian J Biochem Biophys 30(2):133–134PubMed Krishnakantha TP, Lokesh BR (1993) Scavenging of superoxide anions by spice principles. Indian J Biochem Biophys 30(2):133–134PubMed
25.
go back to reference Mills S, Bone K (2000) Principles and practice of phytotherapy. Churchill Livingstone, Oxford Mills S, Bone K (2000) Principles and practice of phytotherapy. Churchill Livingstone, Oxford
26.
go back to reference Morrow GR (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer Suppl 19:S72–S74PubMed Morrow GR (1992) A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer Suppl 19:S72–S74PubMed
27.
go back to reference Ody P (1993) The complete medicinal herbal. Dorling-Kindersley, New York Ody P (1993) The complete medicinal herbal. Dorling-Kindersley, New York
28.
go back to reference Pace J (1987) Oral ingestion of encapsulated ginger and reported self-care action for the relief of chemotherapy-associated N & E. Dissertations Abstracts International 47:3297–B Pace J (1987) Oral ingestion of encapsulated ginger and reported self-care action for the relief of chemotherapy-associated N & E. Dissertations Abstracts International 47:3297–B
29.
go back to reference Pecoraro A, Patel J, Guthrie T, Ndubisi B (1998) Efficacy of ginger as an adjunctive anti-emetic in acute chemotherapy-induced nausea and vomiting. ASHP Mid-Year Clinical Meeting, 429E Pecoraro A, Patel J, Guthrie T, Ndubisi B (1998) Efficacy of ginger as an adjunctive anti-emetic in acute chemotherapy-induced nausea and vomiting. ASHP Mid-Year Clinical Meeting, 429E
32.
go back to reference Shibata C, Sasaki I, Naito H, Ueno T, Matsuno S (1999) The herbal medicine Dai-Kenchu-Tou stimulates upper gut motility through cholinergic and 5-hydroxytryptamine 3 receptors in conscious dogs. Surgery 126(5):918–924PubMed Shibata C, Sasaki I, Naito H, Ueno T, Matsuno S (1999) The herbal medicine Dai-Kenchu-Tou stimulates upper gut motility through cholinergic and 5-hydroxytryptamine 3 receptors in conscious dogs. Surgery 126(5):918–924PubMed
33.
go back to reference Sontakke S, Thawani V, Naik MS (2003) Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: a randomized, cross-over, double-blind study. Indian J Pharmacol 35:32–36 Sontakke S, Thawani V, Naik MS (2003) Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: a randomized, cross-over, double-blind study. Indian J Pharmacol 35:32–36
36.
go back to reference Yamahara J, Huang QR, Li YH, Xu L, Fujimura H (1990) Gastrointestinal motility enhancing effect of ginger and its active constituents. Chem Pharm Bull (Tokyo) 38(2):430–431 Yamahara J, Huang QR, Li YH, Xu L, Fujimura H (1990) Gastrointestinal motility enhancing effect of ginger and its active constituents. Chem Pharm Bull (Tokyo) 38(2):430–431
Metadata
Title
Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting
Authors
Suzanna M. Zick
Mack T. Ruffin
Julia Lee
Daniel P. Normolle
Rivka Siden
Sara Alrawi
Dean E. Brenner
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 5/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0528-8

Other articles of this Issue 5/2009

Supportive Care in Cancer 5/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine